-+ 0.00%
-+ 0.00%
-+ 0.00%

INmune Bio reports AACR preclinical data for INB03 in HER2-positive breast cancer models

PUBT·04/16/2026 12:10:32
Listen to the news
INmune Bio reports AACR preclinical data for INB03 in HER2-positive breast cancer models
  • INmune Bio announced new preclinical data for INB03 (XPro1595) showing improved anti-tumor activity in HER2-positive breast cancer models when combined with tyrosine kinase inhibitors.
  • Results will be presented at AACR 2026 in San Diego, with poster viewing scheduled for April 21.
  • Data indicate INB03 helped overcome resistance to standard HER2-targeted kinase therapies in lab and animal studies.
  • Study also showed reduced metastatic spread, including to brain, supporting a potential positioning in advanced disease with high unmet need.
  • Company framed findings as supportive of advancing INB03 combination approaches into clinical development for patients with treatment resistance or elevated brain metastasis risk.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. INmune Bio Inc. published the original content used to generate this news brief on April 16, 2026, and is solely responsible for the information contained therein.